RadNet (RDNT) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Veracyte (VCYT) has outperformed RadNet (RDNT) over the past year, gaining 24.2% versus a loss of 11.9%. Over five years, RDNT leads with a +138.4% price change compared with -4.4% for VCYT. RadNet is the larger company by market cap ($5.37 billion vs $3.51 billion), about 1.5 times the size, while Veracyte is growing revenue faster (+16.0% vs +11.5%).
On valuation, Veracyte trades at a lower forward P/E (22.4x vs 76.9x for RadNet). Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus -0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RDNT | VCYT |
|---|---|---|
| Share price | $68.21 | $43.60 |
| Market cap | $5.37B | $3.51B |
| 1-day change | -0.58% | +1.02% |
| YTD return | -3.84% | +3.56% |
| 1-year return | -11.94% | +24.22% |
| 5-year return | +138.39% | -4.43% |
| P/E ratio (TTM) | — | 31.14 |
| Forward P/E | 76.93 | 22.36 |
| EPS (TTM) | $-0.27 | $1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04B | $517.14M |
| Revenue growth (YoY) | +11.51% | +16.01% |
| Net income (latest FY) | $-18.65M | $66.35M |
| Gross margin | — | 70.10% |
| Operating margin | 3.04% | 11.17% |
| Net margin | -0.91% | 12.83% |
| 52-week high | $85.84 | $60.91 |
| 52-week low | $50.82 | $29.46 |
| Distance from 52-week high | -20.54% | -28.42% |
| Analyst consensus | none | buy |
| Avg. price target upside | +38.73% | +33.99% |
| Average volume | 711.40K | 1.35M |
| Shares outstanding | 78.70M | 80.39M |
| Employees | 11,000 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VCYT has outperformed RDNT by 36.2 percentage points over the past year.
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -0.9 cents for RadNet.
About RadNet
RDNT stock →RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health.
Health Care · Medical Specialities · 11,000 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
RDNT vs VCYT FAQ
Which is bigger, RadNet or Veracyte?
RadNet (RDNT) is larger, with a market capitalization of $5.37B compared with $3.51B for Veracyte (VCYT).
Which stock has performed better over the past year, RDNT or VCYT?
VCYT returned +24.22% over the past 12 months, compared with -11.94% for RDNT (price return, excluding dividends). Past performance does not predict future results.
Are RadNet and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.